
Apogee rises as long-acting eczema drug heads for phase 3
Positive mid-stage results with Apogee Therapeutics' IL-13 inhibitor APG777 in atopic dermatitis have driven the company's shares up around 20%, as it prepares for a phase 3 programme. The 16-week data from Part A of the APEX study in people with …